Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
Treatments Autoimmune/autoinflammatory
Author: Anoma Ranaweera, Medical Writer, New Zealand. Chief Editor: Dr Amanda Oakley, Dermatologist, New Zealand, January (2015)
Reviewing dermatologist: Dr Ian Coulson (2023)
Edited by the DermNet content department
Introduction Uses How it works How to use Drug interactions Adverse effects Use in pregnancy Use in nursing mothers Paediatric use Geriatric use Renal impairment Hepatic impairment Allergic reactions Depression Weight loss Alcohol consumption
Apremilast (Otezla®, Celgene) is an oral small-molecule inhibitor of the enzyme phosphodiesterase 4, which plays an important role in chronic inflammation associated with psoriasis.
In July 2019, apremilast was also approved by the FDA for treatment of mouth ulcers associated with Behçet disease.
In September 2014, the US Food and Drug Administration (FDA) approved the use of apremilast in patients with plaque psoriasis. It was approved for use in the European Union in January 2015, and New Zealand in psoriasis in November 2016.
Apremilast was approved for the treatment of plaque psoriasis in patients:
The European Medicines Agency's (EMA) granted marketing authorisation throughout the European Union in January 2015 for:
Apremilast was also shown to be effective for the treatment of oral ulceration in Behçet disease.
There are off-label studies demonstrating efficacy in palmoplantar psoriasis, scalp psoriasis, atopic dermatitis, alopecia areata and hidradenitis suppurativa. There have been mixed reports regarding efficacy in sarcoidosis, lichen planus and discoid lupus erythematosus.